Holen Sie sich die Stockscreener-App
27.90
13.09%
3.23
Schlusskurs vom Vortag:
$24.67
Offen:
$25.93
24-Stunden-Volumen:
7.35M
Relative Volume:
1.98
Marktkapitalisierung:
$17.43B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-87.19
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
+18.90%
1M Leistung:
+36.36%
6M Leistung:
+46.92%
1J Leistung:
+587.19%
1-Tages-Spanne:
$25.81
$29.99
1-Wochen-Bereich:
$22.84
$29.99
52-Wochen-Spanne:
$2.10
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
27.90 | 17.43B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey
This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus
Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus
Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus
Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus
Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus
Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa
Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com
Summit Therapeutics stock holds $44 target despite drop - Investing.com
Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India
Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada
Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com
Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus
Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı
BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı
Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus
Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus
Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize
Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks
Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus
Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade
Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus
Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus
Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab - marketscreener.com
Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial - Fierce Pharma
Citi says buy Summit amid ‘significant market confusion’ - TipRanks
Merck gains after latest survival data for Summit’s cancer drug - MSN
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.26%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):